Network meta-analysis finds metabolic surgery superior to GLP-1 agonists for weight loss in obesity
Weight-Loss Surgery Still Leads, But a New Medication Closes the Gap
A network meta-analysis of 20,015 adults with overweight or obesity compared metabolic/bariatric surgery, GLP-1 receptor agonists, and lifes…
Weight-loss surgery still beats drugs overall, but the newest medication tirzepatide closes the gap enough to matter for people who can't ha…
GLP-1 agents and cognitive interventions address obesity and eating disorders via appetite and gut-brain signaling pathways
Why Your Brain Craves Donuts More Than Broccoli
This narrative review examines the cognitive and neural foundations of food preference and reward processing in obesity and eating disorders…
Your brain decides what foods you crave long before your stomach gets a vote, and scientists are finally learning how to rewrite that decisi…
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes
A Common Medication Side Effect May Have a Surprising New Solution
This narrative review evaluates the efficacy and safety of glucocorticosteroid-induced hyperglycemia (SIH) and steroid-induced diabetes (SID…
Doctors are exploring a new way to protect patients from the dangerous blood sugar spikes caused by essential steroid medications.
HFpEF probability scores rule out disease but show limitations in AF and obesity phenotypes
HFpEF probability scores work well for typical cases but struggle with atrial fibrillation and obesity
This systematic review evaluated the performance of HFpEF probability scores (HFA-PEFF and H2FPEF) in patients with heart failure with prese…
Heart failure scores work well for typical cases but lose accuracy in patients with atrial fibrillation or obesity due to altered biological…
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo.
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.
Lixisenatide shows no effect on arterial stiffness in type 2 diabetes with chronic kidney disease
Study finds diabetes drug lixisenatide did not improve artery stiffness in kidney disease patients
A single-center, proof-of-concept randomized controlled trial in 90 people with type 2 diabetes and chronic kidney disease found that 24 wee…
A diabetes drug did not soften arteries in people with kidney disease, showing no improvement in a key heart risk factor after 24 weeks of t…
FDA Approves FOUNDAYO (orforglipron) for chronic weight management in adults with obesity or overweight with comorbidities
The FDA has approved a new daily pill called FOUNDAYO to help adults manage their weight
The FDA has approved FOUNDAYO (orforglipron), an oral GLP-1 receptor agonist, for chronic weight management in adults with obesity or overwe…
FDA approves new daily pill FOUNDAYO for adults to manage weight alongside diet and exercise.